medwireNews: The EMA has adopted a positive opinion recommending that the indication of tofacitinib should be expanded to include psoriatic arthritis (PsA).
This European announcement follows the approval of the Janus kinase inhibitor for the treatment of PsA by the US FDA in December 2017.
Tofacitinib was initially approved in both the USA and Europe for the treatment of adult patients with rheumatoid arthritis and an inadequate response to methotrexate. The drug may now be given to patients with active PsA who have had an inadequate response to, or intolerance of, prior DMARD therapy.
It is recommended that tofacitinib should be taken together with methotrexate, but the FDA cautions against its use in combination with biologic DMARDs or potent immunosuppressants.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group